Satigrel Chemical Properties

Melting point:

124-125°

form 

Solid

color 

White to off-white

Safety Information

Toxicity

LD50 oral in rat: 337mg/kg

Satigrel Usage And Synthesis

Uses

Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively)[1].

References

[1] N Nagakura, et al. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33. DOI:10.1248/bpb.19.828

Satigrel(111753-73-2)Related Product Information

• Clopidogrel
• Rivaroxaban
• Satigrel
• 4,4'-Ethylidenebisphenol
• 4-METHOXYCINNAMONITRILE